To further investigate the role of naringenin in regulating IL-6, CCL2, and TNF-α expression, with particular emphasis on its ability to modulate the AhR, glioma cells were co-treated with the AhR agonist I3C (30 μM). This evidence concerns the gene CCL2 and central nervous system cancer.